Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs LUPIN - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES LUPIN DIVIS LABORATORIES/
LUPIN
 
P/E (TTM) x 60.4 -303.0 - View Chart
P/BV x 13.9 3.9 352.6% View Chart
Dividend Yield % 0.4 0.5 80.0%  

Financials

 DIVIS LABORATORIES   LUPIN
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
LUPIN
Mar-20
DIVIS LABORATORIES/
LUPIN
5-Yr Chart
Click to enlarge
High Rs1,639882 185.8%   
Low Rs1,115505 220.8%   
Sales per share (Unadj.) Rs186.3339.4 54.9%  
Earnings per share (Unadj.) Rs51.0-5.9 -856.9%  
Cash flow per share (Unadj.) Rs57.315.5 370.5%  
Dividends per share (Unadj.) Rs16.006.00 266.7%  
Dividend yield (eoy) %1.20.9 134.3%  
Book value per share (Unadj.) Rs261.8276.7 94.6%  
Shares outstanding (eoy) m265.47453.00 58.6%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x7.42.0 361.7%   
Avg P/E ratio x27.0-116.6 -23.2%  
P/CF ratio (eoy) x24.044.8 53.6%  
Price / Book Value ratio x5.32.5 209.9%  
Dividend payout %31.4-100.9 -31.1%   
Avg Mkt Cap Rs m365,592314,201 116.4%   
No. of employees `00011.818.3 64.7%   
Total wages/salary Rs m5,42329,868 18.2%   
Avg. sales/employee Rs Th4,175.18,400.6 49.7%   
Avg. wages/employee Rs Th457.71,632.0 28.0%   
Avg. net profit/employee Rs Th1,141.8-147.2 -775.8%   
INCOME DATA
Net Sales Rs m49,463153,748 32.2%  
Other income Rs m1,5564,838 32.2%   
Total revenues Rs m51,019158,585 32.2%   
Gross profit Rs m18,71824,849 75.3%  
Depreciation Rs m1,6899,702 17.4%   
Interest Rs m353,630 1.0%   
Profit before tax Rs m18,55116,355 113.4%   
Minority Interest Rs m04 0.0%   
Prior Period Items Rs m039 0.0%   
Extraordinary Inc (Exp) Rs m0-7,521 0.0%   
Tax Rs m5,02311,571 43.4%   
Profit after tax Rs m13,527-2,694 -502.1%  
Gross profit margin %37.816.2 234.1%  
Effective tax rate %27.170.8 38.3%   
Net profit margin %27.3-1.8 -1,560.9%  
BALANCE SHEET DATA
Current assets Rs m46,501154,132 30.2%   
Current liabilities Rs m8,46892,252 9.2%   
Net working cap to sales %76.940.2 191.0%  
Current ratio x5.51.7 328.7%  
Inventory Days Days13182 159.4%  
Debtors Days Days86129 66.4%  
Net fixed assets Rs m25,79789,082 29.0%   
Share capital Rs m531906 58.6%   
"Free" reserves Rs m68,962124,461 55.4%   
Net worth Rs m69,493125,367 55.4%   
Long term debt Rs m017,933 0.0%   
Total assets Rs m80,383249,839 32.2%  
Interest coverage x531.05.5 9,645.0%   
Debt to equity ratio x00.1 0.0%  
Sales to assets ratio x0.60.6 100.0%   
Return on assets %16.90.4 4,504.1%  
Return on equity %19.5-2.1 -905.9%  
Return on capital %26.78.7 306.4%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,23851,450 80.2%   
Fx outflow Rs m12,40519,470 63.7%   
Net fx Rs m28,83331,980 90.2%   
CASH FLOW
From Operations Rs m9,54314,688 65.0%  
From Investments Rs m-6,85411,070 -61.9%  
From Financial Activity Rs m-2,459-8,906 27.6%  
Net Cashflow Rs m23016,853 1.4%  

Share Holding

Indian Promoters % 52.0 46.6 111.6%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 11.8 11.3 104.4%  
FIIs % 19.0 31.9 59.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 10.1 170.3%  
Shareholders   31,796 98,259 32.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SUN PHARMA  PROCTER & GAMBLE HEALTH  NOVARTIS  UNICHEM LAB  ORCHID PHARMA  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Fell Over 1% Today(Closing)

Indian share markets witnessed heavy selling pressure today, pausing the record rally, with all sectors barring telecom, reeling under pressure.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 15, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS